M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
BeOne Medicines secures CHMP backing for TEVIMBRA in early-stage NSCLC
Swiss oncology company BeOne Medicines Ltd (NASDAQ: ONC) (HKEX: 06160; SSE: 688235) announced on Monday that it has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the use of TEVIMBRA (tislelizumab) in combination with...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search